Memantine

Generic Name
Memantine
Brand Names
Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK
Drug Type
Small Molecule
Chemical Formula
C12H21N
CAS Number
19982-08-2
Unique Ingredient Identifier
W8O17SJF3T
Background

Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...

Indication

Memantine is used to manage moderate to severe Alzheimer's dementia .
...

Associated Conditions
Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
Associated Therapies
-
Clinical Trials
Related News

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

First Posted Date
2024-12-11
Last Posted Date
2024-12-11
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
90
Registration Number
NCT06727773
Locations
🇺🇸

Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States

Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury

First Posted Date
2024-03-29
Last Posted Date
2024-08-07
Lead Sponsor
Assiut University
Target Recruit Count
60
Registration Number
NCT06337994
Locations
🇪🇬

Assiut University, Faculty of Medicine, Hospital of Neurology, Psychiatry and Neurosurgery, Assiut, Egypt

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

Phase 2
Recruiting
Conditions
Cirrhosis
Hepatocellular Carcinoma
Interventions
Drug: Namenda
First Posted Date
2023-08-23
Last Posted Date
2023-09-21
Lead Sponsor
Inova Health Care Services
Target Recruit Count
12
Registration Number
NCT06007846
Locations
🇺🇸

Inova Health Care Service, Falls Church, Virginia, United States

🇺🇸

Inova Schar Cancer Institute, Fairfax, Virginia, United States

Efficacy of Memantine in Prevention of Oxaliplatin-induced Peripheral Neurotoxicity

Phase 1
Not yet recruiting
Conditions
Cancer
Interventions
Drug: Placebo
Drug: Memantine
First Posted Date
2023-04-28
Last Posted Date
2023-04-28
Lead Sponsor
Mansoura University
Target Recruit Count
60
Registration Number
NCT05834231

Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors

First Posted Date
2023-04-03
Last Posted Date
2024-12-05
Lead Sponsor
University of Chicago
Target Recruit Count
28
Registration Number
NCT05796752
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

Glutamate Inhibitors in Glioblastoma

First Posted Date
2022-12-23
Last Posted Date
2024-05-10
Lead Sponsor
University of Zurich
Target Recruit Count
120
Registration Number
NCT05664464
Locations
🇨🇭

University Hospital Zurich, Zürich, Zurich, Switzerland

Efficacy of Chinese Traditional Medicine "Smart Soup" in Cognition and Behavior Regulation in Alzheimer's Disease

First Posted Date
2022-09-14
Last Posted Date
2022-09-14
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
180
Registration Number
NCT05538507
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury

Not Applicable
Active, not recruiting
Conditions
Traumatic Brain Injury
Interventions
Drug: Memantine Hydrochloride
First Posted Date
2022-09-08
Last Posted Date
2022-09-08
Lead Sponsor
Minia University
Target Recruit Count
70
Registration Number
NCT05531383
Locations
🇪🇬

Faculty of medecine, Minya, Minia, Egypt

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

First Posted Date
2022-06-14
Last Posted Date
2024-07-08
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
45
Registration Number
NCT05418049
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease

First Posted Date
2021-11-01
Last Posted Date
2021-11-01
Lead Sponsor
Istanbul Medipol University Hospital
Target Recruit Count
27
Registration Number
NCT05102045
Locations
🇹🇷

Istanbul Medipol University, İstanbul, Beykoz, Turkey

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy